Basilea receives $7.3 million to develop antibiotic candidate targeting drug-resistant bacteria

From GlobeNewswire: 2024-12-23 01:15:00

Basilea Pharmaceutica Ltd has received an additional USD 7.3 million in funding from CARB-X to support the development of their antibiotic candidate BAL2420 towards first-in-human clinical studies expected to start in mid-2026. The drug targets Gram-negative bacteria, including strains resistant to current antibiotics, addressing an urgent medical need highlighted by the World Health Organization. Basilea acquired the program earlier this year and previously received a grant for preclinical activities. CARB-X supports projects targeting drug-resistant bacteria and is funded by a consortium of governments and foundations. Basilea is a Swiss biopharmaceutical company committed to addressing severe infections.



Read more at GlobeNewswire: Basilea is awarded additional CARB-X funding to develop new